Market Cap : 59.78 B | Enterprise Value : 68.84 B | PE Ratio : 72.00 | PB Ratio : 3.46 |
---|
NYSE:BSX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NYSE:BSX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Boston Scientific has the Profitability Rank of 6.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:
1. Operating Margin %Boston Scientific's Operating Margin % for the quarter that ended in Jun. 2022 was 15.97%. As of today, Boston Scientific's Piotroski F-Score is 7.
For the Medical Devices subindustry, Boston Scientific's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Boston Scientific's Profitability Rank distribution charts can be found below:
* The bar in red indicates where Boston Scientific's Profitability Rank falls into.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.
Boston Scientific has the Profitability Rank of 6.
Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.
Profitability Rank is based on these factors:
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Boston Scientific's Operating Margin % for the quarter that ended in Jun. 2022 is calculated as:
Operating Margin % | = | Operating Income (Q: Jun. 2022 ) | / | Revenue (Q: Jun. 2022 ) |
= | 518 | / | 3244 | |
= | 15.97 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Good Sign:
Piotroski F-Score is 7, indicates a very healthy situation.
The zones of discrimination were as such:
Good or high score = 8 or 9
Bad or low score = 0 or 1
Boston Scientific has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
Warning Sign:
Boston Scientific Corp operating margin has been in a 5-year decline. The average rate of decline per year is -7.8%.
4. Consistency of the profitability
5. Predictability Rank
Thank you for viewing the detailed overview of Boston Scientific's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.
Wichmann David S | director | UNITEDHEALTH GROUP INC 9900 BREN RD E MINNETONKA MN 55343 |
Brown Vance R | officer: SVP, GC and Corp. Secretary | C/O BOSTON SCIENTIFIC CORPORATION 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752 |
Olson Scott | officer: SVP & Pres, Rhythm Management | C/O BOSTON SCIENTIFIC CORPORATION 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752 |
Scanlon Meghan | officer: SVP,Pres,Urology Pelvic Health | C/O BOSTON SCIENTIFIC CORPORATION 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752 |
Monson Jonathan | officer: VP, Corp Controller and CAO | C/O BOSTON SCIENTIFIC CORPORATION 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752 |
Fujimori Yoshiaki | director | 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752 |
James Donna | director | ONE MIRANOVA PLACE SUITE 1040 COLUMBUS OH 43215 |
Zane Ellen M | director | C/O TUFTS-NEW ENGLAND MEDICAL CENTER 750 WASHINGTON STREET, TUFTS-NEMC #451 BOSTON MA 02111 |
Sununu John E | director | C/O BOSTON SCIENTIFIC CORPORATION 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752 |
Connors Nelda J | director | BOSTON SCIENTIFIC CORPORATION 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752-1234 |
Ludwig Edward J | director | C/O BECTON DICKERSON & CO 1 BECTON DR FRANKLIN LAKES NJ 07417 |
Roux David J | director | C/O BOSTON SCIENTIFIC CORPORATION 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752 |
Dockendorff Charles J | director | COVIDIEN LTD. 15 HAMPSHIRE STREET MANSFIELD MA 02048 |
Macmillan Stephen P | director | 250 CAMPUS DRIVE MARLBOROUGH MA 01752 |
Wang Xin Warren | officer: SVP and Pres, Asia Pacific | C/O BOSTON SCIENTIFIC CORPORATION 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752 |
From GuruFocus
Other Sources
By Zacks 2022-02-11
By tipranks.com 2022-03-23
By Zacks 2021-12-23
By Zacks 2021-12-21
By Seekingalpha 2022-01-31
By Zacks 2021-11-10
By Zacks 2021-10-28
By Zacks 2022-02-01
By Zacks 2022-01-24
By Zacks 2022-03-15
By Zacks 2022-02-02